FindTrial
Sign In

Chemoimmunotherapy

DRUG3 trials

Sponsors

Acerta Pharma BV, Anhui Provincial Hospital, Shanghai Pulmonary Hospital, Shanghai, China

Conditions

Chronic Lymphocytic LeukemiaExtensive-stage Small Cell Lung CancerUnresectable Stage III Non-small-cell Lung Cancer

Phase 1

Radiotherapy to All Residual Lesions After Chemoimmunotherapy
RecruitingNCT06479473
Anhui Provincial HospitalExtensive-stage Small Cell Lung Cancer
Start: 2024-06-01End: 2026-03-31Target: 150Updated: 2024-08-09

Phase 3

Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
Active, not recruitingNCT03836261
Acerta Pharma BVChronic Lymphocytic Leukemia
Start: 2019-02-25End: 2027-01-31Updated: 2024-12-27

Unknown Phase

Induction Therapy With Serplulimab Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer
Not yet recruitingNCT06591910
Shanghai Pulmonary Hospital, Shanghai, ChinaUnresectable Stage III Non-small-cell Lung Cancer
Start: 2024-09-20End: 2030-09-20Target: 50Updated: 2024-09-19

Related Papers

An Indirect Comparison of Zanubrutinib vs Acalabrutinib Plus Venetoclax in Patients With Treatment-Naive CLL.
2026-01-26
Impact of prognostic mutations on outcomes with fixed-duration acalabrutinib-venetoclax combinations versus chemoimmunotherapy: An exploratory analysis from AMPLIFY
Blood2025-11-03
A post hoc safety analysis of fixed-duration acalabrutinib-venetoclax combinations vs chemoimmunotherapy: Results from the phase 3 AMPLIFY trial
Blood2025-11-03
Comparative efficacy of zanubrutinib (ZANU) versus fixed-duration acalabrutinib plus venetoclax (AV) for first-line treatment of chronic lymphocytic leukemia (CLL): A matching-adjusted indirect comparison (MAIC).
Journal of Clinical Oncology2025-05-281 citations
A network meta-analysis (NMA) of efficacy of zanubrutinib versus fixed-duration acalabrutinib plus venetoclax in treatment-naïve (TN) chronic lymphocytic leukemia (CLL).
Journal of Clinical Oncology2025-05-28
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
New England Journal of Medicine2025-02-0558 citations
Advancements in B-Cell Non-Hodgkin's Lymphoma: From Signaling Pathways to Targeted Therapies.
2024-11-124 citations
Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial
Blood2024-11-0513 citations
Validation and Implementation of Flow Cytometry Based Minimal Residual Disease (MRD) Assay for Chronic Lymphocytic Leukemia (CLL) Clinical Studies
Blood2024-11-05
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.
2021-09-1475 citations
The evolving role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia.
2021-01-3011 citations
Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)
Blood2020-11-0419 citations
Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data.
2020-03-1926 citations
Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Blood2019-11-1331 citations
A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with Investigator's Choice of Chemoimmunotherapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) without Del(17p) or TP53 Mutation
Blood2019-11-138 citations